Fed­er­al Cir­cuit rul­ing al­lows Am­gen's Eylea biosim­i­lar to stay on the mar­ket

The US Court of Ap­peals for the Fed­er­al Cir­cuit on Fri­day ruled against Re­gen­eron in a close­ly-watched patent in­fringe­ment case in­volv­ing the New York biotech’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER